Introduction {#s1}
============

Myoclonus--dystonia (MD) is an autosomal dominant disorder that presents with myoclonic jerks and dystonia, although pure myoclonus may be the only manifestation.[@b01] Myoclonic jerks are the predominant feature, usually occurring in the upper body including the neck, shoulders, and arms, and are dramatically responsive to alcohol.[@b02] MD is genetically heterogenous with most mutations or deletions in the epsilon sarcoglycan gene (*SGCE*).[@b03]--[@b05] However, approximately 50% of MD patients are *SGCE* negative, although new genes and loci have been found in some pedigrees.[@b03],[@b04] Oftentimes oral medications do not provide optimal symptom benefit. Deep brain stimulation (DBS) has proven to be an efficient and sustainable therapy for such patients, especially in those who are *SGCE* positive.[@b06]--[@b18] We report on two patients with MD---one *SGCE* positive, the other *SGCE* negative---with isolated myoclonus phenotypes that were refractory to medications and successfully treated with bilateral globus pallidus internus deep brain stimulation (GPi-DBS). We show, through reviewing longitudinal Unified Myoclonus Rating Scale (UMRS) scores, that all aspects of myoclonus, regardless of its location on the body, disappear. This response was realized within 6 weeks of stimulation for both patients, despite their genetic heterogeneity. Furthermore, when combined with published cases in the established literature, there is a suggestion that high frequency with moderate to high voltage drives this therapeutic gain.

Methods {#s2}
=======

Patient 1 {#s2a}
---------

The first patient was a 30-year-old male who had developed jerking movements of the trunk and left arm in childhood. When he walked these movements worsened, and they dampened with running or leaning on his elbows. Genetic testing was positive for an *SGCE* gene mutation and he responded partially to both clonazepam (1 mg three times a day) as well as sodium oxybate (2--3 g daily), but he remained quite impaired. Alcohol (i.e., six shots of vodka) also provided complete symptomatic relief. Family history was negative. On physical examination ([Video 1](#v01){ref-type="other"}) there were frequent myoclonic jerks of his torso and left arm when sitting at rest. Leaning forward attenuated the myoclonus briefly, but it would be exacerbated when walking or doing any other activity such as writing, typing, reaching for items, or eating. There was no myoclonus in his face, right arm, or lower limbs. Stimulation-induced myoclonus was present with claps. He showed no dystonic posturing at rest or with tasks such as writing. His presurgical rest, action, and stimulus UMRS subscores were 21, 38, and 2, respectively.

###### Pre- and Postoperative Examinations for Patient 1. In the pre-surgical state, the patient has persistent truncal and left arm myoclonus while sitting, during rest, and walking. Three years with bilateral globus pallidus internus deep brain stimulation there is no visible myoclonus.

Patient 2 {#s2b}
---------

A 16 year-old female presented with a 3-year history of myoclonic jerks, predominantly on the right side. At the age of 13 years, she developed myoclonic jerks of her right arm and forearm that interfered with writing and holding items. Over the subsequent years, her gait deteriorated because of the emergence of right leg myoclonus triggered by walking. Treatment with trihexyphenidyl (2 mg three times a day), clonazepam (0.5 mg daily), and botulinum toxin injections provided only modest benefit. Genetic testing was negative for *SGCE* mutations and brain magnetic resonance imaging (MRI) was normal. The family history was notable for tic disorder, which our patient also had in the past (i.e., eye blinking tics) before the onset of her condition. On physical examination ([Video 2](#v02){ref-type="other"}) while sitting at rest, there were myoclonic jerks present in her right arm and neck. There was no myoclonus on her left side. When she stood and walked, frequent action-induced myoclonus of the right leg produced an unsteady gait. Stimulation-induced myoclonus was absent. There was no dystonia in her face, neck, or limbs or when performing tasks such as writing. Her presurgical UMRS rest and action myoclonus subscores were 8 and 15, respectively.

###### Pre- and Postoperative Examinations for Patient 2. In the pre-surgical state, the patient has myoclonic jerks of the right arm at rest and when writing. Right leg myoclonus emerges when she walks. At 1 and 3 months with bilateral globus pallidus internus deep brain stimulation, there is no rest or action myoclonus.

Electrode implantation {#s2c}
----------------------

Both patients underwent staged implantation of bilateral DBS electrodes (Medtronic 3389, Minneapolis, MN/USA) into the posteroventrolateral GPi using a Leksell stereotactic frame and O-Arm guidance. The operative target was localized as 20 mm lateral to the midline, 2.5 mm anterior to the middle cerebral peduncle and 4 mm inferior to the commissural line. The target was then cross-correlated with the reformatted Schaltenbrand and Wahren atlas and with quantitative susceptibility mapping[@b19] images showing the GPi. Intraoperative microelectrode recording provided further targeting refinement and postoperative MRI provided confirmation of electrode placement ([Figure 1](#f01){ref-type="fig"}). The pulse generators (Activa SC, Medtronic, Inc) were implanted in the subclavicular region in both patients.

![Postoperative T2-weighted Magnetic Images of Globus Pallidus Internus (GPi) Electrode Positioning with Coordinates in Anterior Commissure - Posterior Commissure Line Space. Patient 1: (A) coronal image of GPi electrodes; (B) axial image showing most ventral tip of electrodes (arrows) in GPi (Left: *X*  =  −19.1, *Y*  =  +2.2, *Z*  =  −4.1; Right: *X*  =  19.1, *Y*  =  2.2, *Z*  =  −4.4). Patient 2: (C) coronal image of GPi electrodes; (D) axial image showing most ventral tip of electrodes (arrows) in GPi (Left: *X*  =  −20.1, *Y*  =  1.5, *Z*  =  −3.2; Right: *X*  =  19.3, *Y*  =  2.0, *Z*  =  −3.5).](tre-06-369-7522-1-g001){#f01}

Postoperative programming commenced 4 weeks from placement of the second electrode and consisted of a monopolar review (pulse width \[PW\] 60 µs, frequency 130 Hz) that determined the threshold for adverse effects such as muscle contractions and visual phosphenes. Contact(s) that provided visible myoclonus reduction together with unwanted side effects were chosen as the therapeutic contact(s). Amplitude was initially set at approximately 20% below the threshold for side effects, and incrementally increased over the subsequent weeks.

Longitudinal unblinded subscores of the UMRS (rest, action, stimulation-induced myoclonus) were evaluated for both patients.

Results {#s3}
=======

Both patients showed complete resolution of myoclonus with stimulation within 1 year of stimulation ([Table 1](#t01){ref-type="table"}). Considerable benefits were evident as early as 1 week (Patient 2), and by 4--6 weeks both rest and action myoclonus were substantially attenuated in both patients. Stimulus-sensitive myoclonus seen in Patient 1 disappeared. Writing improved for both patients along with feeding, typing, and walking. This response has been sustained in both patients, with no evidence of myoclonic jerks over 3 years in Patient 1 ([Video 1](#v01){ref-type="other"}) and 6 months for Patient 2 ([Video 2](#v02){ref-type="other"}).

Table 1Pre- and Postoperative Unified Myoclonus Rating Scale ScoresRestActionStimulus% Change**Patient 1**Preoperative21382Postoperative 6 weeks000−100/−100/−100 7 month240−90/−89/−100 2 years000−100/−100/−100 3 years000−100/−100/−100**Patient 2**PostoperativePreoperative8150--Postoperative 1 week150−88/−67 1 month020−100/−87 2 month000−100/−100 3 month000−100/−100 4 month020−100/−87 5 month010−100/−93 6 month020−100/−87

High-frequency stimulation (130 Hz) was utilized in both patients. Dorsally located contact 2 was associated with robust myoclonus reduction. Right GPi therapeutic amplitudes ranged from 2.5 to 3.4 V and PW 60--140 μs, whereas left GPi therapeutic amplitudes ranged from 3.1 to 3.4 V and PW 60--90 μs.

Patient 2 developed left shoulder rolling movements during the course of the programming that were consistent with tics, because they were stereotyped, suppressible, and associated with a premonitory urge. This tic responded to a longer PW. Patient 1 is no longer on medications for his myoclonus, and Patient 2 is being tapered off oral medications and has not required further botulinum toxin injections.

Discussion {#s4}
==========

DBS of the GPi and ventral intermediate nucleus (VIM) of the thalamus has emerged as a promising therapy for the treatment of refractory MD. Both patients developed isolated myoclonus that was refractory to medical therapy. A robust myoclonus response was appreciated as early as 1 week from initiation of stimulation. Furthermore, there was less variability in the time to significant motor response in our patients than DBS in primary generalized dystonia.[@b20]

The dramatic results seen in Patient 1 are consistent with previously published data in *SGCE*-positive patients. [Table 2](#t02){ref-type="table"} provides a summary of case reports and series of *SGCE*-positive patients treated with GPi-DBS. Myoclonus improvement ranged from 61% to 93% across the studies, with the majority of patients reported as having concomitant dystonia. Long-term sustained benefits from GPi-DBS were even reported at 10 years. *SGCE*-negative patients demonstrated less benefit ([Table 3](#t03){ref-type="table"}) with GPi-DBS, with myoclonus reduction ranging from 30% to 60%. Our *SGCE*-negative patient achieved substantial amelioration of all aspects of her myoclonus; however, the small number of reported *SGCE*-negative cases treated with DBS limits any speculation to a possible differential response to stimulation between *SGCE*-positive and *SGCE*-negative patients.

Table 2Summary of Published Cases of Pallidal Deep Brain Stimulation and *SGCE-*positive Myoclonus--DystoniaStudyNAge (Years) (Range)Disease Duration (Range)UMRS Preop/Postop/% ChangeBFM Preop/Postop/% ChangeContactVoltsPWFreqMean Follow-up (Months)TargetPapuc et al.[@b06]13127 yearsNANANA3714−62NANANANA6GPi (B)Uruha et al.^[@b07]^14237 yearsRest: 29Rest: 9−70144−70NANANANA36GPi (B)Action: 55Action: 16Stimulus: 15Stimulus: 5Functional: 13Functional: 3Kurtis et al.^[@b08]^16361 years2NANA40.522.5−4312.018013514GPi (B)Kuhn et al.^[@b09]^11710 years10111−89264.5−8313.4901309GPi (B)Gruber et al.^[@b10]^1024--6913--63108.4 (mean)36 (mean)−66 (mean)16.8 (mean)13.9 (mean)−48 (mean)NANANANA62GPi/VIM (B)Cif et al.^[@b11]^187 years6913−8118.52.5−86NANANANA20GPi (B)Azoulay-Zyss et al.^[@b12]^530--7118--65 years111636-731616.5−70RC+:1−4.76013018GPi (B)LC+:1−3.76013027620-835.56.0−70RC+:1−3.360130LC+:1−3.2601303388-744.55.0−85RC+:2−2.060130LC+:2−1.6601304706-893.52.5−86RC+:1−3.360130LC+:1−2.9601305868-933.52.5−91RC+:1−3.460130LC+:1−3.560130Contarino et al.^[@b13]^518--50NANANA−23--89 (−72)NANA−17--76 (−56)NA(2.9)(72)(130)12GPi (B)Beukers et al.^[@b14]^329--48NA1468−83184−78RNA2.89013027GPi (B)LNA3.512013027058−172620−23RNA3.06013012GPi (B)LNA3.26013031000−100207−65RNANANANA19GPi (B)LNA360130Roze et al.^[@b15]^252--5433--351700−10025.51−96LC+:12.460130120GPi (B)RC+:1−2.5601302861-9930.51−97LC+:1−2.560130120GPi (B)RC+:1−3.160130Current study132-1Rest: 21Rest: 0Rest: −100NANANALC+:1−2.46013036GPi (B)Action: 38Action: 0Action: −100RC+:1−2.560130Stimulus: 2Stimulus: 0Stimulus: −100[^1]

Table 3Summary of Published Cases of Pallidal Deep Brain Stimulation and *SGCE*-negative Myoclonus--DystoniaStudyNAge (Range)Disease Duration (Range)UMRS Preop/Postop/% ChangeBFM Preop/Postop/% ChangeContactVPWFreqMean Follow-up (Months)TargetSidiropoulos et al.[@b16]2RC+:2−3601301412 years112/32577/32531.3%10.5/1204.5/12057.1%LC+:10−3601304GPi(B)RC+:2,3−2.790125L11+10−2901254934 years29/3259/32569%NANANA11+9−2.7601254.5GPi (B)Kim et al.[@b17]13729 years932 wks8211.8%38.514.4%RC+:0,1−1.61207046GPi (B)LC+:0−1−1.6120706 mos.4551.6%4515.565.6%RC+:1,2,3−2.3150120LC+:0,1,2−2.21201203 yrs3958.1%980%RC+:1,2,3−2.4150120LC+:0,1,2−2.0120135Gruber et al.[@b10]142--NANANANANANANANANANA48GPi VIMCurrent study1166 yearsRest: 8Rest: 0Rest: −100RC+:2−2.6140130Action: 15Action: 1Action: −93NANANALC+:2−3.4901306GPi (B)Stimulus: 0Stimulus: 0Stimulus: 0[^2]

MD tends to produce myoclonic jerks and dystonia in the upper body. The lower limb predominant action myoclonus of Patient 2 is not only unique, but reveals the phenotypic variability of this rare condition.[@b04] Furthermore, while a variable proportion (21--80%) of patients with MD have the *SGCE* mutation, recent identification of mutations in the *RELN* gene in a subset of *SGCE*-negative patients, reflects the genetic heterogeneity of this condition.[@b21] Among the familial cohort found to have the *RELN* mutation, one patient was reported to have lower limb myoclonus.

Benefits across the published studies (Tables 2 and 3) were attained with high-frequency stimulation (range 120--185 Hz) and median amplitudes of 2.34--3.2 V for *SGCE*-negative and *SGCE*-positive patients, respectively. Although the mechanism underlying myoclonus remains unknown, neurophysiological data reveal that GPi neurons have a higher burst frequency with shorter pauses in MD than primary generalized dys onia.[@b22] Pallidal local field potential recordings fromMD patients also demonstrate oscillatory activity in the 3--15 Hz frequency band that synchronize with muscle activity.[@b23] Based on the growing evidence that striatopallidal network changes play a role in MD, we can hypothesize that a possible mechanism for the benefits achieved with GPi-DBS may be rooted in the regularization and desynchronization of abnormal neuronal activity and oscillations, paralleling similar suggested mechanisms of action in Parkinson's disease[@b24] and dystonia.[@b25]

In addition to striatopallidal dysfunction, cerebellar--thalamic network aberrancy[@b26],[@b27] via the parasagittal cerebellum, pontine nuclei, and posterior thalamus has also been implicated in SGCE-positive MD patients.[@b28],[@b29] The therapeutic benefit of thalamic DBS in treating myoclonus in MD patients[@b10] might therefore be related to changes in this network. However, stimulation is usually in the ventral tier of the nucleus, and because of the overlap and lack of clarity of efferent fiber differentiation, it remains uncertain which network is being influenced with stimulation.

In summary, we present two cases of isolated myoclonus in MD, one *SGCE* positive and the other SGCE negative, both of which were effectively treated with bilateral pallidal stimulation. High-frequency stimulation with amplitudes \>2.5 V were needed to reduce the myoclonus. Benefits were realized within 1 month of initial programming and continue to be sustained in both patients.
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[^1]: Abbreviations: \# -, Active Contact(s); (B), Bilateral; BFM, xxx; C+, Case Positive; GPi, Globus Pallidus Internus; L, Left; NA, Not Available; PW, Pulse Width; R, Right; *SGCE*, Epsilon Sarcoglycan Gene; UMRS, Unified Myoclonus Rating Scale; VIM, Ventral Intermediate Nucleus.

[^2]: Abbreviations: (B), Bilateral; BFM, xxx; GPi, Globus Pallidus Internus; NA, Not Available; PW, Pulse Width; *SGCE*, Epsilon Sarcoglycan Gene; UMRS, Unified Myoclonus Rating Scale; VIM, Ventral Intermediate Nucleus.
